Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019, 163(4):318-323 | DOI: 10.5507/bp.2018.059

Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis

Marie Lazarovaa, Dusan Lazarb, Filip Malekc, Jan Vaclavika, Milos Taborskya, Andrew Ignaszewskid
a Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Biophysics, Faculty of Science, Palacky University Olomouc, Czech Republic
c Heart Failure Centre, Hospital Na Homolce, Prague, Czech Republic
d Department of Cardiology, Heart Function Clinics, St. Paul´s Hospital, Vancouver, Canada

Background and Aims: The prognosis of patients with heart failure (HF) is still generally unfavorable. HF with reduced ejection fraction (HFrEF) patients reach target medication doses in very low percentages in daily clinical practice. HF disease management programs (DMP), including nurse and telemedicine support that facilitate achieving target medication doses, may improve the unfavorable prognosis.

Methods: We retrospectively analyzed the data of 738 patients with HFrEF who were followed in a single HF center during the years 1975-2011, for 6.4 (median) years. DMP, nurse and telemedicine support is established at this center.

Results: The group achieved left ventricle (LV) recovery after the HF treatment. The median LV ejection fraction improved from 25.0% at baseline to 50.0% at the time of the latest data collection. The proportion of NYHA II, III and IV classes decreased from 27.6%, 30.2% and 29.7% to 26.6%, 7.2% and 0.1%, respectively while the proportion of NYHA class I increased from 12.5% to 66.1%. Median NT-proBNP decreased from 975.0 to 324.0 pg/mL. The survival of the patient group was favorable; 79.7% survived 18.1 years after diagnosis of HF. A high percentage of the patients received recommended target or higher than target doses of angiotensin-converting enzyme inhibitors (82.0%) and beta-blockers (78.1%).

Conclusion: The established pharmacotherapy resulted from an effective DMP and this contributed to the favorable prognosis.

Keywords: disease management program, heart failure, long term prognosis, pharmacotherapy dose

Received: July 23, 2018; Revised: September 21, 2018; Accepted: September 21, 2018; Prepublished online: October 5, 2018; Published: December 11, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lazarova, M., Lazar, D., Malek, F., Vaclavik, J., Taborsky, M., & Ignaszewski, A. (2019). Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis. Biomedical papers, 163(4), 318-323. doi: 10.5507/bp.2018.059
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18(8):891-975. Go to original source... Go to PubMed...
    2. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009;360(14):1418-28. Go to original source... Go to PubMed...
    3. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376(9744):875-85. Go to original source... Go to PubMed...
    4. Solal CA, Leurs I, Assyag P, Beauvais F, Clerson P, Contre C, Thebault JF, Genoun M. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: The FUTURE survey. Arch Cardiovasc Dis 2012;105(6-7):355-65. Go to original source... Go to PubMed...
    5. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F. Are hospitalized or ambulatory patients with heart failure treated in accordance with European society of cardiology guidelines? Evidence from 12440 patients of the ESC Heart failure long term registry. Eur J Heart Fail 2013;15(10):1173-84. Go to original source... Go to PubMed...
    6. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure. Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106(17):2194-9. Go to original source... Go to PubMed...
    7. Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G. Determinants and clinical outcome of uptitration of ACE-inhibitors and betablockers in patients with heart failure: a prospective European study. Eur Heart J 2017;38(24):1883-90. Go to original source... Go to PubMed...
    8. Konstam MA, Konstam V. Heart failure disease management: a sustainable energy source for the health care engine. J Am Coll Cardiol 2010;56(5):379-81. Go to original source... Go to PubMed...
    9. Inglis SC, Clark RA, McAlister FA, Stewart S, Cleland JG. Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane review. Eur J Heart Fail 2011;13(9):1028-40. Go to original source... Go to PubMed...
    10. Dreves HW, Steuten LMG, Lemmens LC, Baan CA, Boshuizen HC, Elissen AMJ, Lemmens KM, Meeuwissen JA, Vrijhoef HJ. The effectiveness of chronic care management for heart failure: meta-regression analyses to explain the heterogeneity in outcomes. Health Serv Research 2012;47(5):1926-59. Go to original source... Go to PubMed...
    11. Cowie MR. The global relevance of disease management programmes for heart failure. Eur J Heart Fail 2014;16(9):927-8. Go to original source... Go to PubMed...
    12. Gheorghiade M, Albert NM, Curtis AB, Thomas Heywood J, McBride ML, Inge PJ, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Medication Dosing in Outpatients With Heart Failure after Implementation of a Practise-Based Performance Improvement Intervention: Findings From IMPROVE HF. Congest Heart Fail 2012;18(1):9-17. Go to original source... Go to PubMed...
    13. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Rydén L, Thygesen K, Uretsky BF. Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. Circulation 1999;100(23):2312-8. Go to original source... Go to PubMed...
    14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341(10):709-17. Go to original source... Go to PubMed...
    15. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21. Go to original source... Go to PubMed...
    16. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR. Angiotensin-Neprilysin Inhibition versus Enalapril in heart failure. N Engl J Med 2014;371(11):993-1004. Go to original source... Go to PubMed...
    17. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-7. Go to original source...
    18. Braunwald E. Heart failure. JACC-Heart Fail 2013;1(1):1-20. Go to original source... Go to PubMed...
    19. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362(9377):7-13. Go to original source... Go to PubMed...
    20. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150(11):784-94. Go to original source... Go to PubMed...
    21. Castagno D, Jhund PS, McMurray JJV, Lewsey JD, Erdmann E, Zannad F, Remme WJ, Lopez-Sendon JL, Lechat P, Follath F, Höglund C, Mareev V, Sadowski Z, Seabra-Gomes RJ, Dargie HJ. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010;12(6):607-16. Go to original source... Go to PubMed...
    22. Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, Follath F, Goulder M, Willenheimer R. Influence of order and type of drug (bisoprolol vs.enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail 2011;13(7):765-72. Go to original source... Go to PubMed...
    23. Kveiborg B, Major-Petersen A, Christiansen B, Torp-Pedersen C. Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial. Vasc Health Risk Manag 2007;3(1):31-7. Go to PubMed...
    24. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of ß-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98(12):1184-91. Go to original source... Go to PubMed...
    25. Callender T, Woodward M, Roth G, Farzadfar F, Lemarie J-C, Gicquel S, Atherton J, Rahimzadeh S, Ghaziani M, Shaikh M, Bennett D, Patel A, Lam CS, Sliwa K, Barretto A, Siswanto BB, Diaz A, Herpin D, Krum H, Eliasz T, Forbes A, Kiszely A, Khosla R, Petrinic T, Praveen D, Shrivastava R, Xin D, MacMahon S, McMurray J, Rahimi K. Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLos Med 2014;11:e1001699. Go to original source... Go to PubMed...
    26. Krejci J, Hude P, Poloczkova H, Zampachova V, Stepanova R, Freiberger T, Nemcova E, Spinarova L. Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy. Heart Vessels 2016;31(3):416-26. Go to original source... Go to PubMed...
    27. Krejci J, Hude P, Ozabalova E, Mlejnek D, Zampachova V, Svobodova I, Stepanova R, Spinarova L. Improvement of left ventricular systolic function in inflammatory cardiomyopathy: What plays a role? Biomed Pap-Olomouc 2016;160(4):524-32. Go to original source... Go to PubMed...
    28. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Finn Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Eng J Med 2016;375(13):1221-30. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content